恩替卡韦联合转移因子治疗慢性乙肝的效果观察

Observation on effects of entecavir combined with transfer factor on chronic hepatitis B

目的观察恩替卡韦联合转移因子对慢性乙肝患者病毒-DNA(HBV DNA)转阴率及免疫功能的影响。方法选取我院收治的100例慢性乙肝患者作为研究对象,随机分为对照组与观察组,每组50例。对照组单用恩替卡韦治疗,观察组则在此基础上加用转移因子口服液治疗,比较两组HBV DNA、HBe Ag转阴率,治疗前后HBs Ag、HBe Ag水平及免疫功能指标的变化。结果治疗3、6个月后,观察组HBe Ag转阴率分别为60.0%、72.0%,HBV DNA转阴率分别为32.0%、50.0%,二者转阴率均明显高于对照组(P<0.05);观察组HBs Ag水平分别为(2.9±0.3)Ig IU/ml、(2.3±0.2)Ig IU/ml,HBe Ag水平为(205.4±66.3)S/CO、(188.6±34.7)S/CO,均显著低于同时间对照组(P<0.05);与治疗前相比,对照组CD4+和CD8+水平及CD4+/CD8+比值无显著变化,而观察组CD4+水平和CD4+/CD8+比值显著升高,CD8+水平明显降低(P<0.05)。结论恩替卡韦联合转移因子口服液治疗慢性乙肝,可提高患者HBV DNA及HBe Ag转阴率,改善其HBs Ag及HBe Ag水平,强化患者免疫功能,值得推广。

Objective To observe the effects of entecavir combined with transfer factor on the negative conversion ratio and immune function of chronic hepatitis B virus-DNA（HBV DNA）. Methods 100 patients with chronic hepatitis B were selected as research objects and randomly divided into control and observation groups with 50 cases in each group. The control group was treated with entecavir alone, while the observation group was additionally treated with transfer factor oral liquid based on the same treatment as the control group. Comparison was made in the negative conversion ratios of HBV DNA and HBe Ag and the changes in HBs Ag and HBe Ag levels and immune function indexes before and after the treatment. Results Three and six months after the treatment,the negative conversion ratios of HBe Ag in the observation group were 60.0% and 72.0%, and those of HBV DNA were 32.0% and50.0%, respectively. Those ratios in the observation group were all higher than those in the control group（P 〈 0.05）. The HBs Ag levels in the observation group were（2.9 ±0.3） Ig IU/ml and（2.3±0.2） Ig IU/ml, respectively, and the HBe Ag levels were（205.4 ±66.3） S/CO and（188.6±34.7） S/CO. Those levels in the observation group were significantly lower than those at the same time period in the control group（P 〈 0.05）. Compared with the levels before the treatment, the CD4＋and CD8＋levels and the radio of CD4＋to CD8＋in the control group had no significantly changes. While the CD4＋levels and the radio of CD4＋to CD8＋in the observation group increased significantly, and its CD8＋levels significantly decreased（P 〈 0.05）. Conclusion Entecavir combined with transfer factor oral liquid for the treatment of chronic hepatitis B can improve the negative conversion ratios of HBV DNA and HBe Ag, improve the HBs Ag and HBe Ag levels, and strengthen the immune function of patients. It is worthy of promotion.